Skip to main content

Table 1 Patient Characteristics

From: Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life

  IMRT % (n = 75) Control % (n = 87)
Male (n) 72 64
Female (n) 28 36
Mean dose primary tumour 69 Gy 70 Gy
Mean age start RT 59 yrs 59 yrs
Mean interval between RT and Questionnaire 2.3 yrs 2.9 yrs
Tumour Site   
   Hypopharynx 9 9
   Larynx 31 31
   Nasopharynx 7 6
   Oral cavity 7 8
   Oropharynx 37 45
   Thyroid 7 0
   Other 3 1
T-stage   
   T1 16 5
   T2 37 27
   T3 25 33
   T4 22 35
N-stage   
   N0 50 39
   N1 15 13
   N2 36 48
Larynx   
   T1-2 (n) 18 15
   T3-4 (n) 5 12
Oropharynx   
   T1-2 (n) 10 5
   T3-4 (n) 14 27
Concommittant chemotherapy 39 53
Surgery 24 15
Gastrostomy 3 6
Xerostomia related medication 17 20